1. GPCR/G Protein
    Immunology/Inflammation
  2. CXCR
  3. Ladarixin sodium

Ladarixin sodium (Synonyms: DF 2156A)

Cat. No.: HY-19519A Purity: 99.86%
Handling Instructions

Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma.

For research use only. We do not sell to patients.

Ladarixin sodium Chemical Structure

Ladarixin sodium Chemical Structure

CAS No. : 865625-56-5

Size Price Stock Quantity
Solution
10 mM * 1 mL in DMSO USD 330 In-stock
Estimated Time of Arrival: December 31
Solid
5 mg USD 300 In-stock
Estimated Time of Arrival: December 31
10 mg USD 440 In-stock
Estimated Time of Arrival: December 31
25 mg USD 880 In-stock
Estimated Time of Arrival: December 31
50 mg USD 1450 In-stock
Estimated Time of Arrival: December 31
100 mg USD 2300 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Ladarixin sodium:

Top Publications Citing Use of Products

View All CXCR Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma[1].

IC50 & Target[1]

CXCR1

 

CXCR2

 

In Vitro

Ladarixin inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 (IC50 at 0.7 nM)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ladarixin (10 mg/kg; p.o. once a day) reduces allergic airway inflammation in a model of single OVA exposure. Ladarixin reduces allergic airway inflammation, remodeling, and bronchial hyperreactivity in a model of chronic OVA exposure[1].
Ladarixin (10 mg/kg; p.o. once a day for 8 days) reduces pulmonary inflammation and fibrosis induced by bleomycin in mice[1].
Ladarixin (10 mg/kg; p.o. once a day for 3 days) protects mice from cigarette smoke-induced exacerbation of influenza-A infection[1].
Ladarixin is also effective in decreasing CXCL8-induced polymorphonuclear leukocyte infiltration in several animal models without a significant dose-related reduction in systemic neutrophil counts[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Mice (cigarette smoke-induced exacerbation of Influenza-A infection model)[1]
Dosage: 10 mg/kg
Administration: P.o. once a day at days 2, 3 and 4 post-infection
Result: Significantly attenuated the exacerbation in lethality and respiratory changes noted in CSFlu group.
Molecular Weight

397.32

Formula

C₁₁H₁₁F₃NNaO₆S₂

CAS No.
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ladarixin sodium
Cat. No.:
HY-19519A
Quantity:
MCE Japan Authorized Agent: